LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of early stage tongue cancer

Akihiro Miyazaki, Hiromi Nakai, Tomoko Sonoda, Yoshihiko Hirohashi, Mika K. Kaneko, Yukinari Kato, Yoshihiko Sawa, Hiroyoshi Hiratsuka

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: We report that the reactivity of a novel monoclonal antibody LpMab-23 for human cancer-type podoplanin (PDPN) is a predictor for a poor prognosis of tongue cancer. Patients and Methods: The association between LpMab-23-recognizing cancertype PDPN expression and clinical/pathological features were analyzed on 60 patients with stage I and II tongue cancer treated with transoral resection of the primary tumor. Results: In the mode of invasion, the LpMab-23-dull/negative cases were significantly larger in cases with low-grade malignancies and without late cervical lymph node metastasis, than in cases with high-grade malignancies and the metastasis. In the high-grade malignant cases, LpMab-23-positive cases were significantly larger than LpMab-23-dull/negative cases. The Kaplan-Meier curves of the five-year metastasis-free survival rate (MFS) were significantly lower in the LpMab-23 positive patients than in LpMab-23 dull/negative patients. The LpMab-23- dull/negative cases showed the highest MFS in all of the clinical/pathological features and particularly, the MFS of the LpMab-23 positive cases decreased to less than 60% in the first year. In the Cox proportional hazard regression models a comparison of the numbers of LpMab-23 dull/negative with positive cases showed the highest hazard ratio with statistical significance in all of the clinical/pathological features. Conclusions: LpMab-23 positive cases may be considered to present a useful predictor of poor prognosis for early stage tongue cancer.

Original languageEnglish
Pages (from-to)21156-21165
Number of pages10
JournalOncotarget
Volume9
Issue number30
DOIs
Publication statusPublished - Apr 20 2018

Fingerprint

Tongue Neoplasms
Neoplasm Metastasis
Survival Rate
Neoplasms
Proportional Hazards Models
Lymph Nodes
Monoclonal Antibodies

Keywords

  • Antibody
  • LpMab-23
  • Podoplanin
  • Predictor
  • Tongue cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Miyazaki, A., Nakai, H., Sonoda, T., Hirohashi, Y., Kaneko, M. K., Kato, Y., ... Hiratsuka, H. (2018). LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of early stage tongue cancer. Oncotarget, 9(30), 21156-21165. https://doi.org/10.18632/oncotarget.24986

LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of early stage tongue cancer. / Miyazaki, Akihiro; Nakai, Hiromi; Sonoda, Tomoko; Hirohashi, Yoshihiko; Kaneko, Mika K.; Kato, Yukinari; Sawa, Yoshihiko; Hiratsuka, Hiroyoshi.

In: Oncotarget, Vol. 9, No. 30, 20.04.2018, p. 21156-21165.

Research output: Contribution to journalArticle

Miyazaki, A, Nakai, H, Sonoda, T, Hirohashi, Y, Kaneko, MK, Kato, Y, Sawa, Y & Hiratsuka, H 2018, 'LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of early stage tongue cancer', Oncotarget, vol. 9, no. 30, pp. 21156-21165. https://doi.org/10.18632/oncotarget.24986
Miyazaki, Akihiro ; Nakai, Hiromi ; Sonoda, Tomoko ; Hirohashi, Yoshihiko ; Kaneko, Mika K. ; Kato, Yukinari ; Sawa, Yoshihiko ; Hiratsuka, Hiroyoshi. / LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of early stage tongue cancer. In: Oncotarget. 2018 ; Vol. 9, No. 30. pp. 21156-21165.
@article{64d41e431f26406982420bbf135186a3,
title = "LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of early stage tongue cancer",
abstract = "Purpose: We report that the reactivity of a novel monoclonal antibody LpMab-23 for human cancer-type podoplanin (PDPN) is a predictor for a poor prognosis of tongue cancer. Patients and Methods: The association between LpMab-23-recognizing cancertype PDPN expression and clinical/pathological features were analyzed on 60 patients with stage I and II tongue cancer treated with transoral resection of the primary tumor. Results: In the mode of invasion, the LpMab-23-dull/negative cases were significantly larger in cases with low-grade malignancies and without late cervical lymph node metastasis, than in cases with high-grade malignancies and the metastasis. In the high-grade malignant cases, LpMab-23-positive cases were significantly larger than LpMab-23-dull/negative cases. The Kaplan-Meier curves of the five-year metastasis-free survival rate (MFS) were significantly lower in the LpMab-23 positive patients than in LpMab-23 dull/negative patients. The LpMab-23- dull/negative cases showed the highest MFS in all of the clinical/pathological features and particularly, the MFS of the LpMab-23 positive cases decreased to less than 60{\%} in the first year. In the Cox proportional hazard regression models a comparison of the numbers of LpMab-23 dull/negative with positive cases showed the highest hazard ratio with statistical significance in all of the clinical/pathological features. Conclusions: LpMab-23 positive cases may be considered to present a useful predictor of poor prognosis for early stage tongue cancer.",
keywords = "Antibody, LpMab-23, Podoplanin, Predictor, Tongue cancer",
author = "Akihiro Miyazaki and Hiromi Nakai and Tomoko Sonoda and Yoshihiko Hirohashi and Kaneko, {Mika K.} and Yukinari Kato and Yoshihiko Sawa and Hiroyoshi Hiratsuka",
year = "2018",
month = "4",
day = "20",
doi = "10.18632/oncotarget.24986",
language = "English",
volume = "9",
pages = "21156--21165",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "30",

}

TY - JOUR

T1 - LpMab-23-recognizing cancer-type podoplanin is a novel predictor for a poor prognosis of early stage tongue cancer

AU - Miyazaki, Akihiro

AU - Nakai, Hiromi

AU - Sonoda, Tomoko

AU - Hirohashi, Yoshihiko

AU - Kaneko, Mika K.

AU - Kato, Yukinari

AU - Sawa, Yoshihiko

AU - Hiratsuka, Hiroyoshi

PY - 2018/4/20

Y1 - 2018/4/20

N2 - Purpose: We report that the reactivity of a novel monoclonal antibody LpMab-23 for human cancer-type podoplanin (PDPN) is a predictor for a poor prognosis of tongue cancer. Patients and Methods: The association between LpMab-23-recognizing cancertype PDPN expression and clinical/pathological features were analyzed on 60 patients with stage I and II tongue cancer treated with transoral resection of the primary tumor. Results: In the mode of invasion, the LpMab-23-dull/negative cases were significantly larger in cases with low-grade malignancies and without late cervical lymph node metastasis, than in cases with high-grade malignancies and the metastasis. In the high-grade malignant cases, LpMab-23-positive cases were significantly larger than LpMab-23-dull/negative cases. The Kaplan-Meier curves of the five-year metastasis-free survival rate (MFS) were significantly lower in the LpMab-23 positive patients than in LpMab-23 dull/negative patients. The LpMab-23- dull/negative cases showed the highest MFS in all of the clinical/pathological features and particularly, the MFS of the LpMab-23 positive cases decreased to less than 60% in the first year. In the Cox proportional hazard regression models a comparison of the numbers of LpMab-23 dull/negative with positive cases showed the highest hazard ratio with statistical significance in all of the clinical/pathological features. Conclusions: LpMab-23 positive cases may be considered to present a useful predictor of poor prognosis for early stage tongue cancer.

AB - Purpose: We report that the reactivity of a novel monoclonal antibody LpMab-23 for human cancer-type podoplanin (PDPN) is a predictor for a poor prognosis of tongue cancer. Patients and Methods: The association between LpMab-23-recognizing cancertype PDPN expression and clinical/pathological features were analyzed on 60 patients with stage I and II tongue cancer treated with transoral resection of the primary tumor. Results: In the mode of invasion, the LpMab-23-dull/negative cases were significantly larger in cases with low-grade malignancies and without late cervical lymph node metastasis, than in cases with high-grade malignancies and the metastasis. In the high-grade malignant cases, LpMab-23-positive cases were significantly larger than LpMab-23-dull/negative cases. The Kaplan-Meier curves of the five-year metastasis-free survival rate (MFS) were significantly lower in the LpMab-23 positive patients than in LpMab-23 dull/negative patients. The LpMab-23- dull/negative cases showed the highest MFS in all of the clinical/pathological features and particularly, the MFS of the LpMab-23 positive cases decreased to less than 60% in the first year. In the Cox proportional hazard regression models a comparison of the numbers of LpMab-23 dull/negative with positive cases showed the highest hazard ratio with statistical significance in all of the clinical/pathological features. Conclusions: LpMab-23 positive cases may be considered to present a useful predictor of poor prognosis for early stage tongue cancer.

KW - Antibody

KW - LpMab-23

KW - Podoplanin

KW - Predictor

KW - Tongue cancer

UR - http://www.scopus.com/inward/record.url?scp=85045843107&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045843107&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.24986

DO - 10.18632/oncotarget.24986

M3 - Article

AN - SCOPUS:85045843107

VL - 9

SP - 21156

EP - 21165

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 30

ER -